Interim results from the OPTIMAL trial: A phase II clinical trial of combination nivolumab, ipilimumab, and taxane in patients with untreated metastatic non-small cell lung cancer (NSCLC).

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Clarke, JM; Wang, XF; Gu, L; Stevenson, MM; Stinchcombe, T; Ramalingam, S; Antonia, SJ; Shariff, A; Garst, J; Crawford, J; Ready, NE

Published Date

  • May 20, 2020

Published In

Volume / Issue

  • 38 / 15

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X